CD8A and neoplasm: Treatment with 50,000, GL26 tumor lysate-pulsed DC 2.4 cells in young B6 hosts (low-dose therapeutic DC vaccine) resulted in increased peripheral CD8 T cells reactive to Trp-2, the dominant CD8 T cell epitope in GL26 [10], in both GL26-IDH1 and GL26-IDH1R132H hosts (Supplementary Fig. S1B).